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Abstract
Rhinovirus (RV) infections account for approximately two thirds of all virus-induced asthma exacerbations and often result in
an impaired response to b2 agonist therapy. Using an in vitro model of RV infection, we investigated the mechanisms
underlying RV-induced b2 adrenoceptor desensitization in primary human airway smooth muscle cells (ASMC). RV infection
of primary human bronchial epithelial cells (HBEC) for 24 hours produced conditioned medium that caused b2 adrenoceptor
desensitization on ASMCs without an effect on ASMCs viability. Less than 3 kDa size fractionation together with trypsin
digestion of RV-induced conditioned medium did not prevent b2 adrenoceptor desensitization, suggesting it could
potentially be mediated by a small peptide or lipid. RV infection of BECs, ASMCs and fibroblasts produced prostaglandins, of
which PGE2, PGF2a and PGI2 had the ability to cause b2 adrenoceptor desensitization on ASMCs. RV-induced conditioned
medium from HBECs depleted of PGE2 did not prevent ASMC b2 adrenoceptor desensitization; however this medium
induced PGE2 from ASMCs, suggesting that autocrine prostaglandin production may be responsible. Using inhibitors of
cyclooxygenase and prostaglandin receptor antagonists, we found that b2 adrenoceptor desensitization was mediated
through ASMC derived COX-2 induced prostaglandins. Since ASMC prostaglandin production is unlikely to be caused by RV-
induced epithelial derived proteins or lipids we next investigated activation of toll-like receptors (TLR) by viral RNA. The
combination of TLR agonists poly I:C and imiquimod induced PGE2 and b2 adrenoceptor desensitization on ASMC as did the
RNA extracted from RV-induced conditioned medium. Viral RNA but not epithelial RNA caused b2 adrenoceptor
desensitization confirming that viral RNA and not endogenous human RNA was responsible. It was deduced that the
mechanism by which b2 adrenoceptor desensitization occurs was by pattern recognition receptor activation of COX-2
induced prostaglandins.
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Introduction
Acute exacerbations of asthma are the major cause of
morbidity, mortality and health costs related to the disease.
Respiratory viral infections trigger approximately 85% of asthma
exacerbation in adults and children and the mechanisms by which
this occurs remain unclear [1]. Human rhinovirus (RV) belongs to
the Picornaviridae family of positive single stranded RNA viruses and
is implicated in a variety of respiratory disorders ranging from the
common cold to the induction of exacerbations of respiratory
diseases. Of the respiratory viruses that cause asthma exacerba-
tions, RV accounts for about two thirds of all viral-induced asthma
exacerbations [1]. Asthma medications such as corticosteroids and
the epinephrine analogues such as selective b2 agonists are the
most common therapies for asthma management and, during
acute exacerbations, including those caused by respiratory viruses,
b2 agonists are a commonly used rescue medication [2].
Under normal circumstances, airway obstruction in asthma
improves in response to inhaled b2 agonists, however there have
been reports that airway obstruction does not improve with b2
agonists during virally induced asthma exacerbations [3,4]. Reddel
and colleagues reported that in asthmatic adults, during a
respiratory viral infection their exacerbation was characterized
by reduced response to b2 agonists despite having good asthma
control prior to infection, and a good response to b2 agonists prior
to achieving good asthma control [3]. Similarly, Rueter et al.
reported that asthmatic children responded less effectively to b2
agonist therapy in response to a viral-induced exacerbation in
which RV was the most frequently identified virus [4]. These
reports indicate that the underlying cause of this reduced response
to b2 agonists during these exacerbations of asthma may be unique
to a viral infection. The exact causes of exacerbations of asthma
are unknown, however it possible that functional impairment of
the b2 adrenoceptor (b2 AR) may disrupt intrinsic bronchodilation
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through circulating epinephrine and thus result in airflow
limitation characteristic of an exacerbation.
In vivo, the epithelial cells form a physiological barrier in the
airways and are the principal cell type infected by RV in the lower
airways [5] even though there is evidence that underlying
submucosal cells can be infected, perhaps as a consequence of
viremia or compromised epithelial barrier as occurs in asthma or
COPD [6,7]. Since RV-induced inflammation is thought to
contribute to asthma exacerbations, it is likely that the viral-
epithelial infection and the subsequent interaction within the
epithelial mesenchymal trophic unit are critical in mediating viral-
induced exacerbations.
Previous research has suggested that clinical impairment to b2
agonist therapy may be due to desensitization of the b2 AR on
airway smooth muscle cells (ASMCs) [8]. Our group have
previously developed an in vitro model to show that RV infection
of epithelial cells produces a conditioned medium, containing
unknown substances, that when applied to ASMCs, causes
internalisation of the b2 AR, and results in reduced generation
of cyclic adenosine monophosphate (cAMP) in response to a b2
agonist [8]. Furthermore, the effect observed was not due to the
impaired ability to generate cAMP as the adenylate cyclase
activator forskolin induced cAMP response was not reduced. This
in vitro phenomenon may translate to the possible reason why
asthmatic patients with RV-induced asthma exacerbations do not
respond to b2 agonists clinically, however the mechanism by which
it occurs, or the identity of the RV-induced epithelial derived
substance remains unknown.
Eicosanoids are lipid mediators which incorporate the two large
families of prostaglandins and leukotrienes, and their levels are
increased in asthma and during clinical RV infections [9,10]. It
has been shown that of the prostaglandin (PG) family, PGE2 can
cause ASMC relaxation by the induction of cAMP [11]. In doing
so, PGE2 can cause heterologous desensitization of the b2 AR by
either activation of common G protein coupled receptor (GPCR)
kinases, for example GPCR that share common Gs alpha subunits,
or alternatively by direct activation of protein kinase A (PKA) [11–
14]. In contrast, within the leukotriene (LT) family, LTD4 causes
ASMC contraction by activating cystLT1 receptors which are
coupled to Gq alpha subunit proteins and activate the protein
kinase C (PKC) pathway which ultimately increases intracellular
calcium. Surprisingly, LTD4 can also cause desensitization of the
b2 AR [15].
In this study, the identity of the unknown substance/s
responsible for or the mechanism that causes b2 AR desensitiza-
tion in ASMCs were investigated using an in vitro epithelial-ASM
b2 AR model using human primary bronchial epithelial cells
(HBEC) and human primary ASMCs. In the airways, fibroblasts
are structural support cells that lie in close proximity to the
epithelium and smooth muscle, and during RV infection could
contribute to RV induced b2 AR desensitization by their release of
mediators such as prostaglandins. For this reason, the ability of
airway structural cells including ASMCs, epithelial cells and lung
fibroblasts to produce prostaglandins in response to RV infection
and the ability of prostaglandins to cause b2 AR desensitization in
ASMCs were also investigated. We found that RV infection of
epithelial cells resulted in an increase in viral RNA which could
activate toll-like receptors (TLRs) on the ASMC. This resulted in
the generation of COX-2 induced prostaglandins from ASMCs
which in turn caused b2 AR desensitization. Since RV infection of
various airway structural cells also produces prostaglandins, this
could further contribute to b2 AR desensitization.
Materials and Methods
Ethics Statement
The study was approved by the Ethics Review Committee of the
Sydney South West Area Health Service, Royal Prince Alfred
Hospital and The University of Sydney human research ethics
committee. All volunteers provided written informed consent.
Cell culture: Human Bronchial Epithelial Cells, Airway
Smooth Muscle and Fibroblasts
Primary HBEC, ASMC and parenchymal fibroblasts were
isolated from macroscopically normal tissue of patients undergoing
lung resection for thoracic carcinoma or transplantation for end
stage lung disease. All patient details are shown in Table 1 and 2.
HBEC and ASMC were obtained from human bronchial
airways and fibroblasts from lung parenchyma by methods
previously described [16–18]. Briefly, segments of bronchus were
dissected free from the surrounding parenchyma, cut open and
washed in Hanks’ balanced salt solution (HBSS) (Invitrogen,
Victoria, Australia). The epithelium was removed and collected
into 75 cm2 flasks with bronchial epithelial growth medium
(BEGM) (Clonetics, California, USA). In doing so this exposes the
underlying bands of smooth muscle, which were then gently
separated from the underlying connective tissue in small bundles
(smooth muscle cell explants). The explants were transferred into
25 cm2 flasks and covered with a minimal amount of Dulbecco’s
Modified Eagle Medium (DMEM) containing 1% antibiotics:
20 U/L of penicillin, 20 mg/mL of streptomycin, 2.5 mg/mL of
amphotericin B, and 10% Fetal Bovine Serum (FBS) (all
purchased from Invitrogen). Fibroblasts were isolated from
Table 1. Demographic data of study patients in RV infection
of airway structural cells and prostaglandin production.
Patient
# Cell Type Sex Age Disease Sample
1 Fibroblasts F 43 Emphysema Transplant
2 Fibroblasts F 65 Ca Resection
3 Fibroblasts M 68 SCCA Resection
4 Fibroblasts F 38 Emphysema Transplant
5 ASMC F 65 Ca Resection
6 ASMC M 76 SCCA Resection
7 ASMC F 59 NSCCA Resection
8 ASMC F 66 Ca Resection
9 ASMC M 62 Emphysema Transplant
10 ASMC F 56 Bronchiectasis Transplant
11 ASMC M 47 Emphysema Transplant
12 ASMC F 43 Emphysema Transplant
13 ASMC M 71 Asthma Biopsy
14 ASMC F 49 Asthma Biopsy
15 ASMC F 47 Asthma Biopsy
16 ASMC M 45 Asthma Biopsy
17 HBEC F 54 Emphysema Biopsy
18 HBEC M 73 Ca Resection
19 HBEC M 64 NSCCA Resection
20 HBEC F 72 NSCCA Resection
21 HBEC M 63 Emphysema Transplant
doi:10.1371/journal.pone.0056058.t001
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Table 2. Demographic data of study patients in the
characterisation of the mechanism of RV-induced b2
adrenoceptor desensitization.
Patient
# Cell Type Sex Age Disease Sample
1 HBEC F 71 Ca Resection
2 HBEC M 58 Ca Resection
3 HBEC F 60 Emphysema Transplant
4 HBEC M 74 Ca Resection
5 HBEC F 44 Emphysema Transplant
6 HBEC M 66 Ca Resection
7 HBEC F 43 Emphysema Transplant
8 HBEC M 57 Emphysema Transplant
9 HBEC M 58 No disease Transplant
10 HBEC F 68 COPD/Ca Resection
11 HBEC M 55 Emphysema Transplant
12 HBEC F 60 Emphysema Transplant
13 HBEC M 54 NSCCA Resection
14 HBEC M 58 Emphysema Transplant
15 HBEC M 30 Cystic Fibrosis Transplant
16 HBEC M 61 Pulmonary fibrosis Transplant
17 HBEC M 63 Asthma Biopsy
18 HBEC F 51 Emphysema Transplant
19 HBEC M 57 NSCCA/COPD Resection
20 HBEC F 55 Ca Resection
21 HBEC F 59 NSCCA/COPD Resection
22 ASMC M 56 a1 anti-trypsin
deficiency
Transplant
23 ASMC M 57 a1 anti-trypsin
deficiency
Transplant
24 ASMC M 71 Ca Resection
25 ASMC M 49 Emphysema Transplant
26 ASMC M 33 Asthma Biopsy
27 ASMC M 66 SCCA Resection
28 ASMC M 38 Asthma Biopsy
29 ASMC M 22 No disease Biopsy
30 ASMC M 22 Asthma Biopsy
31 ASMC M 20 No disease Biopsy
32 ASMC M 65 Ca Resection
33 ASMC M 21 Asthma Biopsy
34 ASMC M 61 Emphysema Transplant
35 ASMC M 56 Emphysema Transplant
36 ASMC M 22 Asthma Biopsy
37 ASMC F 43 Emphysema Transplant
38 ASMC F 19 Asthma Biopsy
39 ASMC M 65 NSCCA Resection
40 ASMC M 41 Emphysema Transplant
41 ASMC M 59 Emphysema Transplant
42 ASMC M 57 Sarcoidosis Transplant
43 ASMC M 66 NSCCA Resection
44 ASMC M 70 NSCCA Resection
45 ASMC F 45 Emphysema Transplant
46 ASMC M 70 Ca Resection
Table 2. Cont.
Patient
# Cell Type Sex Age Disease Sample
47 ASMC M 58 NSCCA/COPD Resection
48 ASMC M 59 Ca Resection
49 ASMC M 61 Ca Resection
50 ASMC M 80 Ca Resection
51 ASMC M 75 NSCCA Resection
52 ASMC M 72 NSCCA Resection
53 ASMC M 64 NSCCA Resection
54 ASMC M 43 Pulmonary fibrosis Transplant
55 ASMC M 52 Ca Resection
56 ASMC M 52 Pulmonary fibrosis Transplant
57 ASMC M 59 Emphysema Transplant
58 ASMC F 62 Emphysema Transplant
59 ASMC M 74 SCCA Resection
60 ASMC M 58 Ca Resection
61 ASMC F 71 Ca Resection
62 ASMC F 29 Pulmonary
hypertension
Transplant
63 ASMC F 44 Emphysema Transplant
64 ASMC M 70 Ca Resection
65 ASMC F 43 Emphysema Transplant
66 ASMC F 56 Emphysema Transplant
67 ASMC F 53 Pulmonary fibrosis Transplant
68 ASMC M 66 NSCCA Resection
69 ASMC M 57 Emphysema Transplant
70 ASMC F 59 Ca Resection
71 ASMC F 59 Ca Resection
72 ASMC M 75 NSCCA/COPD Resection
73 ASMC F 41 Ca Resection
74 ASMC F 62 Ca Resection
75 ASMC M 67 NSCCA Resection
76 ASMC F 15 Pulmonary
hypertension
Transplant
77 ASMC M 58 No disease Transplant
78 ASMC F 68 NSCCA/COPD Resection
79 ASMC M 61 Ca Resection
80 ASMC M 55 Emphysema Transplant
81 ASMC F 60 Emphysema Transplant
82 ASMC M 54 NSCCA Resection
83 ASMC F 44 Emphysema Transplant
84 ASMC F 51 Pulmonary fibrosis Transplant
85 ASMC M 81 No disease Unknown
86 ASMC M 71 NSCCA Resection
87 ASMC F 50 Emphysema Transplant
88 ASMC M 35 Emphysema Transplant
89 ASMC M 30 Cystic Fibrosis Transplant
90 ASMC M 30 Cystic Fibrosis Transplant
91 ASMC F 66 Ca Resection
92 ASMC M 53 Emphysema Transplant
93 ASMC M 54 Emphysema Transplant
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resected lung tissue by seeding 1–2 mm3 pieces of parenchymal
tissue into DMEM supplemented with 10% FBS and 1%
antibiotics in 75 mm2 flasks. Both cell types were incubated at
37uC in a humidified atmosphere of 5% CO2-95% air.
The medium was replenished every 5 days for the first 10–20
days, and within this time, cell growth occurred. The cells were
passaged (split 1:3) with a solution of trypsin [0.05% wt/vol in
HBSS] containing 1 mM EDTA. The cells were maintained in
DMEM supplemented with 1% antibiotics in 10% FBS whilst
HBEC were maintained in BEGM. All cells were tested for
mycoplasma contamination and only mycoplasma free cells were
selected and passaged once they reached confluence. ASMCs and
fibroblasts at passages 3–7 and HBEC at passages 2–3 were used
for experiments.
RV Propagation and Ultraviolet Inactivation of RV (UVi-
RV)
Human RV serotype-16 were propagated in Ohio HeLa cells
and purified using a 100,000 kDa molecular weight cut off
(MWCO) filter as previously described [19,20]. RV concentration
was determined by virus titration as described previously [21]. In
some experiments RV or conditioned medium was UV inactivated
in 24 well plates containing 200 mL of sample/well at a distance of
5 cm from a 30 W UV light source (germicidal lamp G30T8,
Sankyo Denki, Japan) for 15 minutes. Successful UV inactivation
of RV was established by a virus titration and was used as a non-
infectious virus control.
Rhinovirus Infection of BEC, Fibroblasts and ASMCs and
Prostaglandin Production
HBEC were seeded at a concentration of 6.46104 cells/mL in
BEGM, while fibroblasts and ASMCs were seeded at 3.26104
cells/mL in 10%FBS/DMEM in 6 well plates for 72 hours. The
total number of cells after 72 hours was assessed and wells were
then either left uninfected (control) or exposed to UV inactivated
RV or live RV at a multiplicity of infection (MOI) of 1. The cells
were placed on a shaker (100 rpm) for 15 minutes at room
temperature before being incubated at 37uC at 5% CO2. After 1
hour the cells were washed with HBSS and replaced with fresh
BEGM or 10%FBS DMEM before being incubated at 37uC in a
humidified atmosphere of 5% CO2-95% air. After 24 hours, the
supernatant was purged with nitrogen, collected and stored at
280uC for ELISA and the number of remaining viable cells was
estimated for each well using trypan blue exclusion and manual
cell counting to normalize prostaglandin release to cell number.
ELISAs
PGE2, PGD2, PGF2a, PGI2 metabolite 6ketoPGF1a, CystLT
and LTB4 ELISAs were purchased from Cayman Chemicals,
Michigan, USA. The assays were carried out according to the
manufacturer’s instructions. The detection range for each assay
was PGE2 7–1000 pg/mL; PGD2 78–5000 pg/mL; PGF2a 3–
500 pg/mL; 6ketoPGF1a 1–1000 pg/mL; CystLT 7–1000 pg/mL
and LTB4 3–500 pg/mL. Prostaglandin ELISA results were
normalised to cell number and expressed as concentration per
16106cells.
ELISA kits for IL-6 and IL-8 were purchased from R&D
Systems (Minneapolis, USA) and BD Biosciences (California,
USA) respectively. ELISAs were carried out according to the
manufacturers’ instructions. The detection limits of these assays
were: 7–1000 pg/mL (IL-6) and 15–2000 pg/mL (IL-8).
Reagents
Prostaglandins (PG) D2, E2, F2a, the PGI2 analogues: MRE-269
(selective) and Beraprost (non-selective) – both of which are being
used in clinical trials for the treatment of pulmonary hypertension,
the selective COX-2 inhibitor celecoxib (Cayman Chemicals),
indomethacin and 3-isobutyl-1-methylxanthine (IBMX) were
dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Missouri,
USA) and stored at 280uC prior to use. Isoprenaline (Sigma-
Aldrich) was dissolved in water before use. The protease trypsin
was dissolved in Hank’s balanced salt solution (HBSS) (both from
Invitrogen) prior to use and to inhibit its digestive activity during
experimentation 0.1% bovine serum albumin (BSA) (Invitrogen)
was used. The TLR 3 agonist polyinosinic : polycytidylic acid (Poly
I:C) (Sigma-Aldrich) and TLR 7/8 agonist imiquimod (InvivoGen,
California, USA) were dissolved in DMSO and H2O respectively
and stored at 220uC. The pro-opiomelanocortin (POMC) protein
was purchased ready to use from ABCAM (Cambridge, UK) and
the 1.2 kDa ‘‘substance X’’ peptide was synthesized by Auspep
(Victoria, Australia) and dissolved in H2O. Both protein and
peptide were stored at 280uC before use. The prostaglandin
receptor antagonists AH6809 (EP1–3, DP1); CAY10441 (IP);
AL8810 (FP); BWA868C (DP2); L-161,982 (EP4) were purchased
from Cayman Chemicals and dissolved in DMSO and stored at
280uC prior to use. In experiments where a single or mix of
prostaglandin receptor antagonists or vehicle were used, the final
concentrations and formulation for experimentation were chosen
according to its use in previous studies to successfully inhibit their
specified receptor and they consisted of AH6809 (1025 M) [22];
CAY10441 (1026 M) [23]; AL8810 (1025 M) [24]; BWA868C
(1025 M) [25]; L-161,982 (1026 M) [26] or the sum of each
corresponding amount of vehicle (DMSO).
Assessment of Cell Viability and Number
In some experiments, cell viability was assessed by means of
measuring mitochondrial activity using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium (MTT) (Sigma) assay as previously
Table 2. Cont.
Patient
# Cell Type Sex Age Disease Sample
94 ASMC M 58 Emphysema Transplant
95 ASMC M 64 Emphysema Transplant
96 ASMC F 68 Ca Resection
97 ASMC M 71 SCCA Resection
98 ASMC F 51 Emphysema Transplant
99 ASMC M 58 No disease Biopsy
100 ASMC M 77 Ca Resection
101 ASMC M 60 NSCCA Resection
102 ASMC F 58 NSCCA Resection
103 ASMC F 67 Ca Resection
104 ASMC M 76 Ca Resection
105 ASMC F 63 Ca Resection
106 ASMC M 26 Bronchiolitis
Obliterans
Transplant
107 ASMC M 66 NSCCA Resection
108 ASMC F 62 Emphysema Transplant
Key: ASMC= airway smooth muscle cells; HBEC=human bronchial epithelial
cells; SCCA= Small cell carcinoma; NSCCA=Non small cell carcinoma;
COPD=Chronic obstructive pulmonary disease; Ca=Cancer.
doi:10.1371/journal.pone.0056058.t002
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described [27]. In other experiments, total cell number was
determined by a manual trypan blue exclusion cell count using a
haemocytometer and an estimation of the total number of cells
was calculated.
Generation of HBEC Derived Conditioned Medium
Primary HBEC were seeded at a concentration of 56104 cells/
mL in 75 cm2 culture flasks with 10 mL of BEGM until .90%
confluent. Briefly, RV or UVi-RV (MOI = 2) or BEGM was added
to the confluent cell monolayers for 1 hour with orbital shaking at
37uC. The cells were then washed with HBSS and fresh BEGM
was added and the cells were incubated at 37uC in a humidified
atmosphere of 5% CO2 for 24 hours. In experiments with the
COX inhibitor indomethacin, infection occurred in the presence
of the drug at 161025 M in BEGM and replacement BEGM also
contained the drug at 161025 M. Control, UVi-RV and RV
generated conditioned medium was collected 1 day after infection.
All conditioned medium (control, UVi-RV and RV) were UV
treated by placing 250 mL of conditioned medium into each well of
a 12-well tissue culture plate at a distance of 5 cm from a UV lamp
for 5 minutes to ensure that all RV was inactivated before being
applied undiluted on primary human ASMCs to assess b2 AR
function.
Primary human ASMCs were incubated with control, UVi-RV
and RV conditioned medium for 3 days. In experiments assessing
whether prostaglandins, TLR agonists or total extracted RNA
from conditioned medium can cause b2 AR desensitization,
treatments were applied in BEGM or control conditioned
medium. In experiments utilizing prostaglandin receptor antago-
nists to determine the prostaglandin responsible for b2 AR
desensitization, ASMCs were pretreated with the antagonist 1
hour prior and during the 3 day incubation period with
conditioned medium. b2 AR function on ASMCs was assessed
by the functional cAMP assay and where appropriate ASMC
viability was assessed using an MTT assay.
Evidence of epithelial RV infection was assessed by the
measurement of RV induced IL-6 by ELISA. The induction of
proteins present in RV conditioned medium was assessed using the
Quantipro BCA assay kit (Sigma-Aldrich) and 1-D protein gel
electrophoresis with silver staining.
cAMP Assay
To assess b2 AR function cells were stimulated with the b
agonist isoprenaline (1027 M) for 5 minutes in the presence of the
phosphodiesterase inhibitor IBMX (1025 M) in HBSS. The cells
were then lysed in a solution of H2O with 0.03% (v/v) Tween-20
and 5 mM HEPES buffer by vigorous pipetting. The amount of
isoprenaline induced cAMP in the lysate samples was quantified
using an Alphascreen cAMP Assay Kit (Perkin Elmer, Massachu-
setts, USA) according to the manufacturer’s instructions.
Quantipro BCA Assay Kit
Protein concentration in conditioned medium was determined
using the bicinchoninic acid (BCA) assay kit according to the
manufacturer’s instruction.
Protein Gel Electrophoresis
Conditioned medium was prepared as follows for gel electro-
phoresis: 5 mL of loading buffer (2% sodium dodecyl sulphate
(SDS), 7.5% glycerol, 31.25 mM Tris-HCl (pH 6.8), 0.0025%
bromophenol blue, 200 mM DTT (all from Sigma-Aldrich) was
added to 25 mL of conditioned medium and denatured at 95uC for
5 minutes. Five mL of Precision plus Protein Dual Xtra Molecular
Standard ladder (Bio-Rad, New South Wales, Australia) was
added in a separate lane of each gel to indicate the size of the
visualised bands, while 20 mL of prepared protein samples was
added to each separate lane.
Twenty mL of protein samples were loaded onto a 4%
polyacrylamide stacking gel (25% (v/v) SDS Tris pH 6.8; 10%
(v/v) 37.5:1 acrylamide (Bio-Rad); 0.1% (v/v) tetramethylethyle-
nediamine (Sigma-Aldrich); 0.1% (v/v) ammonium persulfate
(Sigma-Aldrich); in Milli-Q H20) and separated by SDS-poly-
acrylamide electrophoresis on a 10% polyacrylamide gel (25% (v/
v) SDS Tris pH 8.8; 25% (v/v) 37.5:1 acrylamide; 0.1% (v/v)
tetramethylethylenediamine; 0.1% (v/v) ammonium persulfate; in
Milli-Q H20) at 150 V for 90 minutes before they were prepared
for silver staining. Gels were visualized and analysed using an
IS4000MM Kodak imaging system and software (Kodak Scientific
Imaging Systems, New York, USA).
Silver Staining
After protein electrophoresis, the gels were transferred into a
50 mL fixative solution (50% (v/v) methanol, 12% (v/v) glacial
acetic acid, 0.05% (v/v) 37% formaldehyde (Sigma-Aldrich), Milli-
Q H2O) for 30 minutes on an orbital shaker. The fixative solution
was then removed and three washes of 50% ethanol in Milli-Q
H2O were carried out each for 20 minute intervals. The gels were
then washed three times with Milli-Q H2O and incubated with
20% w/v thiosulfate solution for 1 minute then washed three times
again with Milli-Q H2O. The gels were incubated in 0.2% w/v
silver nitrate in the dark for 20 minutes before being washed twice
in Milli-Q H2O and then incubated in developer solution (6% (w/
v) Na2CO3, 0.05% (v/v) 37% formaldehyde, 2% (v/v) of
thiosulfate solution as described above, in Milli-Q H2O) until
the bands were clear. The development was stopped by three
washes in Milli-Q H2O and the bands were captured using the
Kodak imaging system.
Protease Digestion
In order to assess whether RV-induced epithelial derived
proteins in the conditioned medium may be responsible for
causing b2 AR desensitization, large proteins were digested using
the protease trypsin and the conditioned medium was reassessed
for its ability to induce b2 AR desensitization on ASMCs.
Initial experiments involved the optimization of multiple
variables including the amount of protease required for digestion,
time for sufficient digestion of conditioned medium proteins and
the appropriate concentration of inhibitor substance to avoid
cytotoxic effects on ASMCs. Protein gel electrophoresis followed
by silver staining of digested products validated the digestion
process, while MTT assays were used to validate the safety of
optimized concentrations of protease and time of digestion on
ASMC viability over 3 days. As the protein concentration in
conditioned medium varied from batch to batch, control and RV
conditioned medium from multiple batches were pooled in these
experiments.
Since endogenous proteases are necessary for homeostatic cell
function, the use of protease inhibitors to stop the exogenous
protease digestion may affect ASMC function and viability.
Therefore since trypsin digestion can be safely stopped using
saturation with BSA instead of the use of protease inhibitors,
trypsin instead of other proteases was selected for enzymatic
digestion of the conditioned medium to assess b2 AR desensitiza-
tion.
Briefly, 3–4 batches of control and RV conditioned medium
were pooled to a total of 4–6 mL and trypsin was added (500 mg/
mL) and the mixture was allowed to incubate in a water bath at
Rhinovirus Induced b2 Adrenoceptor Desensitization
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37uC for 24 hours. After the digestion, 0.1% BSA was added to the
mixture to saturate and stop the enzymatic digestion. Since the
presence of trypsin and BSA may affect the outcome of results,
trypsin (.20 kDa) was also inactivated by removal using the
Amicon ultra-15 centrifugal filtration unit (Millipore, Massachu-
setts, USA) with 3 kDa molecular weight cut off (MWCO). The
undiluted trypsin digested conditioned medium was applied to
ASMCs to assess b2 AR desensitization using a functional cAMP
assay.
PGE2 Affinity Chromatography Column
PGE2 columns filled with 1 mL of PGE2 affinity sorbent (mouse
anti-PGE2 covalently bound to Sepharose 4B) were purchased
from Cayman Chemicals. PGE2 purification and extraction was
carried out according to the manufacturer’s instruction. Briefly,
the column was first washed with 0.1 M phosphate buffer solution,
and then 4 mL of pooled control or RV conditioned medium was
loaded onto the column. The flow-through product free of PGE2
(confirmed by PGE2 ELISA) was collected for experimentation.
The column was then washed twice with 2 mL of distilled water,
and a 2 mL solution containing 95% absolute ethanol and 5%
distilled water was used to elute the column bound PGE2. The
eluted solution was completely evaporated by vacuum centrifuga-
tion for 2 hours at 37uC and purified PGE2 was reconstituted in
1 mL of BEGM for experimentation. Depletion of PGE2 was
confirmed by ELISA.
Molecular Weight Fractionation
Amicon ultra-15 centrifugal filtration units of 100, 50, 30, 10,
3 kDa MWCO filters were purchased from Millipore. Initially,
15 mls of control or RV conditioned medium was pooled and
loaded into the initial 100 kDa MWCO filter unit and centrifuged
at 40006g for 30 minutes. One mL of the flow-through product
was collected for experimentation and the remainder was loaded
into the 50 kDa filter unit and centrifuged as before. The
sequential filtration, fractionation and sampling were carried out
from the 100 kDa to the 3 kDa MWCO filter unit. Flow-through
fractions were used to treat ASMCs to assess the relationship
between the size fraction and its ability to cause b2 AR
desensitization.
Mass Spectrometry
In order to identify whether there was a difference in the
peptide profiles between the control and RV conditioned medium
that were in the ,3 kDa fraction, mass spectrometry (MS) was
carried out as previously described by Ly et al [28]. In brief, the
samples were purified using Ziptips (Millipore) as per the
manufacturer’s instructions. The peptides were then analysed by
liquid chromatography-mass spectrometry analysis (LCMS).
Sample peptides were concentrated and desalted onto a ZORBAX
300SB-C18 trap (5 mm, 5 6 0.3 mm, Agilent Technologies,
Victoria, Australia) with 5% (v/v) acetonitrile at 10 mL/min. After
a 10 minute wash the pre-column was switched into line with an
in-house prepared fritless nano column which had been packed
with ReproSil-Pur 120A˚ C18 (Dr Maisch GmbH, Ammerbuch-
Entringen, Germany) and peptides eluted using a acetonitrile
gradient over 30 minutes at 300 nL/min. High voltage (2300 V)
was applied through a low volume tee (Upchurch Scientific,
Washington, USA) at the column inlet and the outlet positioned
1.5 cm from the orifice of a QSTAR Elite hybrid tandem mass
spectrometer (Applied Biosystems, California, USA). Positive ions
were generated by electrospray and the QSTAR operated in
information dependent acquisition mode. A survey scan was
acquired (350–1750 m/z, 0.5 s) and the 3 most abundantly
multiplied charged ions (counts .30, charge state 2 to 4)
sequentially selected by Q1 for MS/MS analysis. Nitrogen was
used as the collision gas and optimum collision energy was
automatically chosen based on charge state and mass. Tandem
mass spectra were accumulated with smart exit enabled (quali-
ty = 20 or up to 2 s (65–2000 m/z)).
Database Searching
Peak lists were generated using Analyst QS 2.0 and were
searched using Mascot v2.3 (Matrix Science, Massachusetts, USA)
against the LudwigNR 2012 Q1 database. The following criteria
were used: precursor and product ion tolerances 0.2 Da; variable
modifications of methionine oxidation; trypsin and one allowed
missed cleavage specified; and decoy search enabled. Similar
searches were performed but with no enzyme specified.
RNA Purification
Total RNA including micro RNA was purified using the
miRNeasy Mini purification kit (Qiagen, Victoria, Australia) as
per the manufacturer’s instructions. Total RNA concentration and
quality was determined using a spectrophotometer (Nanodrop
ND-1000).
Analysis of Data
All data were checked for normal distribution and when the
results were not parametrically distributed, the dataset was log
transformed prior to statistical analysis using GraphPad Prism
Version 5 (GraphPad Software, California, USA). Results were
analysed by paired Student’s t-tests and 1 or 2-way analysis of
variance (ANOVA) where appropriate and Bonferroni post test
comparison with corresponding controls. In all cases, a P value of
less than or equal to 0.05 was considered statistically significant.
Results
RV-induced Conditioned Medium and b2 Adrenoceptor
Desensitization
Conditioned medium was initially characterised and is defined
as the supernatant obtained from primary HBEC exposed to no
virus (control), UVi-RV or replication competent RV. Since RV
infection of HBECs induces IL-6, measurement of IL-6 induction
was used as a positive control marker to indicate viral infection
[8,29]. Total protein content and IL-6 concentration in the
supernatant from HBEC exposed to UVi RV was not different
from the non exposed cells. However supernatant from RV
infected HBEC, contained a significant increased total protein
content as well as IL-6 concentration compared to unstimulated
cells (p,0.05, Figure 1 A-B). Primary ASMCs treated with UVi
RV conditioned medium from HBEC did not alter isoprenaline
induced cAMP levels compared to control conditioned medium.
In contrast RV-induced conditioned medium from HBEC resulted
in a decreased isoprenaline induced cAMP from ASMCs
compared to treatment with control conditioned medium and
therefore was indicative of b2 AR desensitization (p,0.05,
Figure 1C). RV-induced b2 AR desensitization was independent
of an effect on cell viability as assessed by MTT (p.0.05,
Figure 1D).
Molecular Weight Fractionation and Trypsin Digestion of
Conditioned Medium
The RV-induced mediator from HBEC responsible for b2 AR
desensitization was investigated by size fractionation of the
conditioned medium. ASMCs treated with RV-induced condi-
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tioned medium that was either not fractioned or was size
fractioned through 100, 50, 30, 10 or 3 kDa molecular weight
cut off (MWCO) filters, all decreased isoprenaline induced cAMP
compared to the control conditioned medium from the corre-
sponding fraction (p,0.05, Figure 2A).
To determine whether the RV-induced mediator was a protein,
the conditioned medium was trypsin digested. Complete trypsin
digestion was confirmed by absence of detection by ELISA of two
different sized proteins IL-6 (26 kDa) and IL-8 (8 kDa) (Figure S1)
and further confirmed by the absence of protein bands using
protein gel electrophoresis and silver staining (Data not shown).
ASMCs treated with RV-induced conditioned medium that was
trypsin digested and fractionated through the 3 kDa filter to
remove trypsin still caused decreased isoprenaline induced cAMP
compared to their respective controls (p,0.05, Figure 2B). RV-
induced conditioned medium that was digested with trypsin and
was not fractionated but saturated with BSA to inhibit the activity
of trypsin, also caused reduced isoprenaline induced cAMP (Figure
S2). These results imply that the mediator responsible for b2 AR
desensitization was not trypsin digestible and had a molecular
weight of ,3 kDa.
RV-induced Release of Prostaglandins from HBECs,
ASMCs and Lung Fibroblasts
Since the responsible mediator was ,3 kDa and not trypsin
digestible, prostaglandin release in response to RV infection was
investigated. Primary human HBECs, ASMCs and lung
fibroblasts exposed to UVi RV at MOI = 1 did not induced
further prostaglandin release compared to basal control levels.
RV infection with a MOI = 1 induced the release of PGE2,
PGF2a, PGD2 and the PGI2 metabolite 6ketoPGF1a from all
cell types when compared to basal control levels (p,0.05,
Figure 3 A–L).
Effect of Prostaglandins on b2 Adrenoceptor
Desensitization
Since RV induced the release of prostaglandins from primary
airway structural cells, their effect on b2 adrenoceptor desensiti-
zation was investigated. PGE2 and PGF2a, but not PGD2 (10
27-
1025 M), caused a concentration dependent decrease in isopren-
aline induced cAMP compared to the respective vehicle controls
(p,0.05, Figure 4A). MRE-269, but not beraprost (1027-1025 M)
caused a concentration dependent decrease in isoprenaline-
induced cAMP compared to the respective vehicle controls
(p,0.05, Figure 4B).
Effect of Depleting PGE2 from Conditioned Medium
Of the RV-induced prostaglandins, only PGE2, PGI2 and
PGF2a caused b2 AR desensitization. With PGI2 being unstable
and difficult to measure, and the effects of PGF2a on b2 AR
desensitization being minimal the investigation focused on the
role of PGE2. Conditioned medium from uninfected, UVi-RV
Figure 1. Conditioned medium derived from RV-infected HBEC had increased concentrations of protein and IL-6; and caused a
decrease in isoprenaline induced cAMP from ASMCs without an effect on ASMC viability. (A–B) HBEC (n = 4) were uninfected (Control) or
exposed to: UV inactivated RV (UVi-RV) or replication competent RV (RV) at an MOI = 2 for 24 hours. The concentration of total protein and IL-6 in the
supernatant was measured using a BCA assay and ELISA respectively. (C–D) ASMCs (n = 14) were treated with conditioned medium from HBEC (n = 3)
that were uninfected, (Control) or exposed to: UV inactivated RV (UVi-RV) or replication competent RV (RV) at an MOI = 2 for 3 days. Isoprenaline
induced cAMP was measured using a cAMP functional assay and ASMC viability was measured using a MTT assay. Data represent mean 6 SEM.
Statistical differences were examined for using 1-way ANOVA with Bonferroni post test comparison to control treatment *p,0.05.
doi:10.1371/journal.pone.0056058.g001
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or RV infected HBEC was depleted of PGE2 passed through a
PGE2 immuno affinity column compared with the original
conditioned medium (p,0.05, Figure 5A). RV-induced condi-
tioned medium depleted of PGE2 still caused decreased
isoprenaline induced cAMP from ASMCs (p,0.05, Figure 5B).
However the PGE2 depleted RV-induced conditioned medium
induced the release of PGE2 from ASMCs (p,0.05, Figure 5C).
The PGE2 captured by the affinity column was eluted and was
found to be concentrated 4 fold by the extraction process
(Figure 5A). Even from the control conditioned medium, the
PGE2 was sufficient to decrease the isoprenaline induced cAMP
from ASMCs and was comparable to that obtained with RV-
induced conditioned medium (p,0.05, Figure 5B). Eluted PGE2
from RV-induced conditioned medium caused a greater
decrease in isoprenaline induced cAMP from ASMCs compared
with ASMCs treated with eluted PGE2 extracted from control
conditioned medium (p,0.05, Figure 5B).
Effect of COX Inhibitors and Prostaglandin Receptor
Antagonists on RV-induced b2 Adrenoceptor
Desensitization
The autocrine action of ASMC derived prostaglandins on b2
AR desensitization was investigated with pharmacological tools
using the non selective COX inhibitor indomethacin, a COX-2
selective inhibitor celecoxib and a combination of PGE2, PGD2,
PGF2a and PGI2 receptor antagonists.
PGE2 release from ASMCs treated with conditioned medium in
the presence of indomethacin and celecoxib was significantly
attenuated compared to RV-induced conditioned medium in the
presence of vehicle (p,0.05, Figure 6 A and C).
ASMCs treated with RV-induced conditioned medium resulted
in a decreased isoprenaline induced rise in cAMP in the presence
of vehicle (p,0.05), however this effect was absent when ASMCs
was treated with indomethacin, celecoxib or a combination of
prostaglandin receptor antagonists in the presence of RV-induced
conditioned medium (p.0.05 Figure 6 B, D and E).
Since non specific prostaglandin inhibition prevented RV-
induced b2 AR desensitization, individual receptor antagonists of
prostaglandin receptors were used to determine which prostaglan-
din was responsible for RV-induced b2 AR desensitization.
However RV-induced conditioned medium still caused b2
adrenoceptor desensitization on ASMCs even in the presence of
individual PGE2, PGI2, PGD2 or PGF2a receptor antagonists
(p,0.05, Figure S3).
Mass Spectrometry Analysis of Conditioned Medium
In order to investigate whether a small peptide was present in
the RV conditioned medium and could be responsible for b2 AR
desensitization on ASMCs, an overall peptide profile present in the
less than 3 kDa fraction of the uninfected, UVi-RV and RV-
induced conditioned medium was obtained using mass spectrom-
etry.
A comparative proteomic analysis of uninfected, UVi-RV and
RV-induced conditioned medium resulted in the identification of a
1.2 kDa peptide with an 11 amino acid sequence ‘‘GDEQPL-
TENPR’’ that was present only in the RV-induced conditioned
medium. The peptide is a fragment of the pro-opiomelanocortin
(POMC) protein, which is a polypeptide that is cleaved to give rise
to a super family of neuro-peptides. The 1.2 kDa peptide was
synthesized and along with POMC, did not influence ASMC
viability, PGE2 induction or b2 AR desensitization (data not
shown).
RNA Levels in Conditioned Medium and Effect of TLR
Activation on b2 Adrenoceptor Desensitization on
ASMCs
Toll-like receptors (TLR) are pathogen pattern recognition
receptors that are present on ASMCs [30]. Activation of TLRs on
ASMCs by small synthetic molecules, pure viral RNA and even
fragments of RNA only 5 nucleotides long are immuno-
stimulatory [31,32]. Since activation of the bacterial recognition
receptors TLRs 2 & 4 result in the induction of COX-2 induced
prostaglandins [33,34], we investigated whether RV RNA as a
result of infection can activate the viral recognition receptors TLR
3, 7 and 8 and also induce COX-2 mediated prostaglandins which
may then cause b2 AR desensitization on ASMCs.
When conditioned medium generated from HBEC (n = 3) was
pooled, the total RNA measured in RV-induced conditioned
medium (300.25 ng/mL) was almost 6 times higher than RNA in
control conditioned medium (53.91 ng/mL). RV infection pro-
duces both ssRNA and dsRNA during replication and whether
Figure 2. Size fractionation and trypsin digestion of HBEC
conditioned medium still resulted in RV-induced b2 adreno-
ceptor desensitization on ASMCs. HBEC (n = 6) were uninfected
(Control) or infected with replication competent RV (RV) at an MOI = 2
for 24 hours to generate conditioned medium. The conditioned
medium was pooled and serially fractionated through ultrafilters with
molecular weight cut offs ranging from 100-3 kDa. Alternatively,
conditioned medium from HBEC (n = 3) that was uninfected (Control)
or exposed to: UV inactivated RV (UVi-RV) or replication competent RV
(RV) at an MOI = 2 for 24 hours was digested in the presence of 500 mg/
mL of trypsin for 24 hours at 37uC and trypsin removed using a 3 kDa
MWCO ultrafilter. ASMCs (n = 6) were then treated with unfiltered or
size fractionated control or RV-induced conditioned medium (A) or
3 kDa fractionated conditioned medium which was undigested or
digested with trypsin (B) for 3 days. Isoprenaline induced cAMP was
measured using a cAMP functional assay. Data represent mean 6 SEM.
Statistical differences were detected using multiple paired Student’s t-
tests (A) or a 1-way ANOVA with Bonferroni post test (B) comparisons to
control conditioned medium *p,0.05.
doi:10.1371/journal.pone.0056058.g002
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activation of TLRs 3 and 7/8 using synthetic analogues can result
in induction of PGE2 and b2 AR desensitization on ASMCs were
investigated.
Treatment with poly I:C (50 mg/mL) or imiquimod (30 mg/mL)
induced PGE2 from ASMCs compared to BEGM alone (p,0.05)
and did not alter isoprenaline induced cAMP (Figure 7 A&B).
Treatment with the combination of poly I:C and imiquimod
caused an additive induction of PGE2 similar to the levels caused
by RV-induced conditioned medium from ASMCs and caused a
decrease in isoprenaline induced cAMP (p,0.05, Figure 7 A&B).
Treatment with 300.25ng/mL of RNA extracted from RV-
induced conditioned medium induced PGE2 release and decreased
isoprenaline induced cAMP from ASMCs compared to the control
treatment without RNA (p,0.05, Figure 7 C&D). These effects
did not occur with treatment of RNA extracted from control
conditioned medium.
Since the extraction of total RNA from RV induced
conditioned medium may include endogenous RNA from HBEC
as well as viral RNA, the effect of viral RNA and endogenous
RNA on b2 AR desensitization was investigated. Treatment with
RNA obtained from RV-16 stock in the presence of control
conditioned medium decreased isoprenaline induced cAMP from
ASMCs compared to the control treatment without RNA
(p,0.05, Figure 7E) but treatment with endogenous RNA
extracted from HBEC lysate did not alter isoprenaline induced
cAMP (p.0.05, Figure 7F) when compared to control conditioned
medium without RNA. This suggests that viral RNA in RV
induced conditioned medium may be responsible for b2 AR
desensitization on ASMCs.
Discussion
Using an in vitro model we previously showed that factor(s)
released from RV infected epithelial cells cause b2AR desensiti-
zation on ASMCs [8]. In the present study, we aimed to identify
the responsible mediators and pathways which are involved and
we confirmed that RV infection of primary HBEC produced
conditioned medium that when used to treat ASMCs reduces
isoprenaline induced cAMP, thus functionally causing b2 AR
desensitization. It was deduced that the responsible mediator was
less than 3 kDa which meant it could potentially have been a lipid
such as a prostaglandin. We showed that RV infected airway cells
produce prostaglandins and, since PGE2 is known to desensitize
the b2 AR [11], the effect of other members of the prostaglandin
family on the b2 AR was examined in vitro. It was found that
PGF2a, PGE2 and MRE-269 caused b2 AR desensitization and
with the use of pharmacological tools it was deduced that b2 AR
desensitization occurred via autocrine prostaglandins from
ASMCs. Mass spectrometry analysis yielded a single peptide
present in the less than 3 kDa conditioned medium fraction;
however it alone had no influence on b2 AR function. Since RNA
was detected at greater levels in RV-induced conditioned medium
than the control conditioned medium, we investigated RNA as the
potential mediator causing b2 AR desensitization via the activation
of TLR receptors. Using synthetic analogs of double stranded (ds)
and single stranded (ss) RNA it was found that their combination
caused PGE2 induction from ASMCs and b2 AR desensitization
and similarly, total RNA extracted from RV-induced conditioned
medium also caused PGE2 induction from ASMCs and b2 AR
desensitization. Since human endogenous RNA extracted from
Figure 3. RV infected primary HBECs, ASMCs and lung fibroblasts induced prostaglandins. HBECs (n = 5) (A–D), ASMCs (n = 12) (E–H) and
lung fibroblasts (n = 4) (I–L) were uninfected (Control) or exposed to: UV inactivated RV (UVi-RV) or replication competent RV (RV) at an MOI= 1 for 24
hours. Levels of PGE2 (A, E, I), PGF2a (B, F, J), PGD2 (C, G, K) and the PGI2 metabolite 6ketoPGF1a (D, H, L) in the supernatant were measured using ELISA
and normalised to total cell number calculated using manual cell counting with trypan blue exclusion after 24 hours. Data represent mean 6 SEM.
Statistical differences were detected using 1-way ANOVA with Bonferroni post test comparisons to prostaglandin levels in the presence of control
conditioned medium *p,0.05.
doi:10.1371/journal.pone.0056058.g003
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HBEC did not cause this effect but RNA extracted from RV did, it
was deduced that viral RNA produced during RV replication was
required to cause b2 AR desensitization.
Like all G protein coupled receptors (GPCRs), desensitization of
the b2 AR occurs physiologically to prevent over activation of the
receptor. This can be achieved by the mechanism of homologous
Figure 4. PGF2a, PGE2, and MRE-269 reduced isoprenaline induced cAMP from ASMCs but not PGD2 and Beraprost. ASMCs (n = 8)
were treated with vehicle (DMSO) (0 M- solid black), PGF2a, PGD2 and PGE2 (10
27-1025 M) (A) or ASMCs (n = 5) were treated with beraprost and MRE-
269 (1027-1025 M) (B) in BEGM for 3 days. Isoprenaline induced cAMP was measured using a cAMP functional assay. Data represent mean6 SEM and
are expressed as a percentage of the appropriate vehicle. Statistical differences were detected using 1-way ANOVA with Bonferroni post test
comparisons to the respective vehicle *p,0.05.
doi:10.1371/journal.pone.0056058.g004
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desensitization i.e. activation of the receptor by its own defined
agonist, for example, activation of the b2 AR by a b2 agonist
causing b2 AR desensitization. Alternatively this can also occur by
heterologous desensitization i.e. activation of another GPCR
resulting in b2 AR desensitization because of common down-
stream cross-regulation of the signal pathways of the G protein
subunits [12,14]. Prostaglandin receptors are all GPCRs, and it is
well documented that PGE2 can cause heterologous desensitiza-
tion of the b2 AR by means of downstream cross talk of GPCR
kinases (GRK) but also by activation of the PKA pathway through
the EP2 and EP4 receptors [12,13].
Trian et al. first developed this in vitro model as used in this
study to explore and understand why patients with naturally
occurring RV-induced asthma exacerbations do not respond well
to b2 agonists. We previously deduced that the substance was
released only from RV infected HBEC [8]. Findings in the current
investigation confirmed the result of Trian et al that RV infection
of HBEC indeed produced increased levels of mediators in
conditioned medium which may cause b2 AR desensitization. In
this study our data indicates that the responsible mediator for b2
AR desensitization was less than 3 kDa and not affected by trypsin
digestion and therefore could potentially be a lipid or a trypsin-
resistant peptide.
It has already been reported by Seymour et al that in vivo RV
infection results in the up regulation of COX-2 enzymes as
detected by immunostaining of bronchial mucosal biopsies [9].
However they did not examine which prostaglandin was released
or which cell the prostaglandins came from. There are a limited
Figure 5. PGE2 was successfully depleted from RV-induced conditioned medium from HBEC; but it still caused RV-induced b2
adrenoceptor desensitization and further induced PGE2 from ASMCs. HBEC (n = 3) were uninfected (Control) or exposed to: UV inactivated
RV (UVi-RV) or replication competent RV (RV) at an MOI = 2 for 24 hours to generate conditioned medium. Conditioned medium was depleted of PGE2
using affinity chromatography. The original conditioned medium, conditioned medium depleted of PGE2 and PGE2 eluted product were collected
and the levels of PGE2 (A) was measured using ELISA. ASMCs (n = 6) were then treated with the original conditioned medium, conditioned medium
depleted of PGE2 or PGE2 eluted product in BEGM for 3 days. Isoprenaline induced cAMP was measured using a cAMP functional assay (B) and the
level of PGE2 released by ASMCs due to each component was measured using ELISA (C). Data represent mean 6 SEM. Statistical differences were
detected using a 2-way ANOVA (A&B) and 1-way ANOVA (C) with Bonferroni post test comparisons to the respective control conditioned medium
*p,0.05; respective components of the original conditioned medium #p,0.05.
doi:10.1371/journal.pone.0056058.g005
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number of studies that have investigated RV-induced eicosanoids
from airway structural cells and their impact in the respiratory
system. Within this context and of the few investigations in this
area, Oliver et al reported that RV infection of alveolar
macrophages induces the release of PGE2 [35]. Kuo et al found
that RV infection of epithelial cells resulted in the induction of
PGE2, and RV-induced PGE2 could potentially influence airway
remodelling via its effect on altering neighbouring cellular
Figure 6. Pharmacological inhibition of prostaglandins prevented the effect of RV-induced b2 adrenoceptor desensitization on
ASMCs. ASMCs (n = 5) were pretreated for 1 hr with appropriate vehicles or indomethacin (1025 M) (A,B), celecoxib (1025 M) (C,D) or a combination
of prostaglandin receptor antagonists (combination composition: AH6809 (1025 M); CAY10441 (1026 M); AL8810 (1025 M); BWA868C (1025 M); L-
161,982 (1026 M)) (E) and maintained for a further 3 days in the presence of conditioned medium from HBEC (n = 1) that were uninfected (Control) or
exposed to: UV inactivated RV (UVi-RV) or replication competent RV (RV) at an MOI= 2 for 24 hours. PGE2 (A, C) was measured using ELISA and
isoprenaline induced cAMP (B, D, E) was measured using a cAMP functional assay. Data represent mean 6 SEM. Statistical differences were detected
using 1-way ANOVA with Bonferroni post test comparisons to control conditioned medium pretreatment in each group *p,0.05.
doi:10.1371/journal.pone.0056058.g006
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behaviour such as cell migration [17]. In the present study we
extended the research beyond just PGE2, to show that RV
infection of primary HBECs, ASMCs and lung fibroblasts can
induce the release of various prostaglandin isotypes other than just
PGE2. The amount of each prostaglandin released in response to
RV infection varied amongst the various airway cell types tested,
and although this issue is beyond the scope of this study, it could
potentially highlight differences in the contribution of each
individual prostaglandin as infection progresses from the epithe-
lium to sub-mucosal cells. This raises the possibility of a pool of
potential candidates singly or in combination that may be
responsible for desensitization of the b2 AR.
The investigation showed that RV infection of airway cells
produced prostaglandins and PGE2 can cause desensitization of
the b2 AR, which is in keeping with the study by Penn et al. who
showed that PGE2 can cause desensitization of the b2 AR, [11].
Since it has not been previously explored, the role of other
prostaglandins was investigated and it was found that PGF2a can
also cause desensitization of the b2 AR, suggesting it may share
common GRKs with the b2 AR. Similarly, the PGI2 analogue
MRE-269 also has the ability to cause b2 AR desensitization
suggesting this desensitization may involve PKA as well as GRK
cross talk. Therefore it is possible that RV infection may result in
an increase of prostaglandins in the vicinity and may result in b2
AR desensitization on ASMCs. The ability of PGF2a to induce b2
AR desensitization was minimal compared to those by MRE-269
and PGE2, and since PGI2 is extremely unstable and only its
inactive metabolite could be measured, it was considered unlikely
to be sufficiently stable in the model to cause b2 AR desensitization
on ASMCs. Since we showed PGE2 caused b2 AR desensitization
most prominently compared to other prostaglandins, it was
investigated whether HBEC derived PGE2 could be responsible
by its depletion from conditioned medium. However, removal of
PGE2 from conditioned medium did not affect b2 AR desensiti-
zation on ASMCs. It was then hypothesized that the autocrine
action of ASMC derived prostaglandins may instead be respon-
sible for b2 AR desensitization on the ASMCs, as PGE2 depleted
RV-induced conditioned medium further induced approximately
10 fold higher levels of PGE2 in comparison to control conditioned
medium. This suggested that the unidentified mediator, although
not HBEC derived PGE2, induces PGE2 and potentially other
prostaglandins from ASMCs.
To investigate if ASMC derived prostaglandins were responsible
for b2 AR desensitization, ASMCs was treated with indomethacin
and this prevented b2 AR desensitization from occurring when
ASMCs were exposed to RV-induced HBEC conditioned
medium. These findings were similar to the study by Guo et al,
who showed that exogenously applied interleukin (IL)-1b induced
COX-2 induction of PGE2 caused b2 AR desensitization and this
was also preventable with indomethacin treatment in primary
human ASMCs [12]. However IL-1b is a 17 kDa protein and
since RV-induced conditioned medium from HBEC does not
contain IL-1b and the unknown mediator is smaller than 3 kDa it
was excluded as the mediator in this investigation [8,36,37]. It was
further verified that COX-2 induced autocrine prostaglandins
were responsible for b2 AR desensitization as treatment with
celecoxib also prevented this effect. The hypothesis that autocrine
prostaglandins were causing b2 AR desensitization was also
confirmed when ASMCs treated with a combination of prosta-
glandin antagonists prevented b2 AR desensitization in response to
RV-induced HBEC conditioned medium exposure. Therefore this
suggests that RV infection of HBEC may be producing
unidentified mediators which cause increased activity of COX-2
and production of prostaglandins from ASMCs which act
autocrinely to cause b2 AR desensitization.
An attempt was made to determine which prostaglandin isotype
was responsible for b2 AR desensitization by pre-treating ASMCs
with different prostaglandin receptor antagonists only to find that
none of the antagonists alone prevented b2 AR desensitization.
The receptor antagonists available are designed to be selective for
individual prostaglandin receptors however, in some circumstanc-
es; the antagonists are not selective enough and lack the ability to
differentiate between the very similar receptors of PGE2 and
PGD2. In addition, prostaglandins are also very pleotropic and can
cross activate each other’s receptors [38,39]. In future, with more
defined and specific antagonists available or by genetically
knocking down specific prostaglandin receptors, it may be possible
to delete individual autocrine prostaglandins and to identify the
combination of prostaglandin isotypes involved in RV-induced b2
AR desensitization.
Using mass spectrometry it was found that a 1.2 kDa peptide
was present in RV-induced conditioned medium, but not in the
control conditioned medium. The 1.2 kDa peptide is a fragment
from the POMC protein which is a precursor for various
hormones and ultradian rhythm neuro-peptides [40]. However
treatment of ASMCs with the 1.2 kDa peptide or the polypeptide
POMC did not cause b2 AR desensitization on ASMCs,
suggesting they are not the responsible mediators or that a
combination of mediators are required.
Since RV-induced conditioned medium cause b2 AR desensi-
tization through an immuno-stimulatory process such as via the
process of autocrine COX-2 induction, and the unidentified
mediator was small, it was hypothesized that the responsible
mediator might be viral RNA or viral RNA fragments.
Results of the study showed that the use of the synthetic TLR 7/
8 agonist imiquimod and the TLR 3 agonist poly I:C alone slightly
increased PGE2 release from ASMCs but did not alter isopren-
aline induced cAMP. This result is in agreement with that of
Cooper et al, who also showed that poly I:C promotes inflamma-
tory mediator release [41]. However in order to mimic the
presence of both viral ssRNA and dsRNA fragments which would
occur during RV replication, the combination of both synthetic
agonists of the TLRs 3 and 7/8 was used and it was found that it
caused b2 AR desensitization as well as an additive induction of
Figure 7. The combination of TLR 3 and 7/8 agonists, and RNA extracted from RV-induced conditioned medium or RV stock caused
PGE2 induction and b2 adrenoceptor desensitization on ASMCs, but not RNA extracted from HBECs. Control and RV-induced
conditioned medium was generated from HBEC (n = 2) and pooled. ASMCs (n = 6) were treated with this pooled control or RV-induced conditioned
medium; or untreated (BEGM), poly I:C (50 mg/mL), imiquimod (30 mg/mL) and poly I:C & imiquimod (50 mg/mL, 30 mg/mL respectively) in BEGM or in
the presence of the control conditioned medium for 3 days (A, B). (Figure C-F) Control and RV-induced conditioned medium was generated from
HBEC (n = 3) and pooled. Total RNA was extracted from: control- (53.91 ng/mL), RV-induced conditioned medium (300.25 ng/mL), RV stock (567.35 ng/
mL) and cell lysate collected from a sub-confluent 75 cm2 flask of HBEC (300 ng/mL) using a miRNeasy Mini purification kit and amount of RNA
quantified using a spectrophotometer. ASMCs (n = 6) were treated with pooled control conditioned medium (control), or total extracted RNA
collected from those sources in the presence of control conditioned medium for 3 days. PGE2 was measured using an ELISA (A, C) and isoprenaline
induced cAMP was measured using a cAMP functional assay (B, D-F). Data represent mean 6 SEM. Statistical differences were detected using 1-way
ANOVA with Bonferroni post test comparisons to respective BEGM, control conditioned medium only (Control) or Poly I:C *p,0.05, #p,0.05.
doi:10.1371/journal.pone.0056058.g007
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PGE2 from ASMCs equivalent to those levels produced by RV-
induced conditioned medium. This was further explored by
showing that RNA extracted from an equal volume of RV-
induced HBEC conditioned medium was higher than the control
conditioned medium, and that RNA collected from RV-induced
conditioned medium caused ASMC b2 AR desensitization. Total
RNA extracted from RV-induced conditioned medium could
include both endogenous human RNA as well as RV RNA and it
is difficult to distinguish these small nucleotide fragments. It was
confirmed that equal concentrations of RNA extracted from pure
RV-16 caused PGE2 induction and b2 AR desensitization on
ASMCs but this was not the case for endogenous human RNA
extracted from HBEC lysate, which suggests that foreign viral
RNA is required.
RV is a positive sense ssRNA virus and during replication,
dsRNA are formed in order to generate more copies of the ssRNA
genome to be packed into new virions. However, like many RNA
viruses, RV replication is susceptible to RNA polymerase error with
a rate of 1023 and 1024 errors/nucleotide/cycle of replication [42].
This could result in incorrect or incomplete formation of new
ssRNA strands which may not be packed into new virion capsules
and may accumulate intracellularly. Continuing RV replication
would eventually result in the accumulation of large amounts of
both incomplete and complete viral ss/dsRNA inside the cell. This
viral RNA could escape the cell via transporting vesicles, cellular
pores or upon cell lysis which could expose foreign RV RNA as well
as new infectious RV progeny to neighbouring cells. In the case of
the ASMC, it is possible that RV RNA could potentially trigger
TLRs to activate COX-2 induced prostaglandins and therefore
result in b2 AR desensitization. Whilst UVi-RV contains RV RNA,
the virions cannot replicate and therefore there is no increase in
viral RNA. Whether b2 AR desensitization is restricted to asthma,
or not is not known. It has been reported that greater RV replication
occurs in epithelial cell derived from people with asthma [43] so
there is a possibility that there would be greater RV RNA.
Alternatively, it is possible that in people without asthma or airway
hyper-reactivity, RV-induced b2 AR desensitization can occur
during colds and remains clinically unnoticed. It is uncertain
whether full length RV RNA or RNA fragments activate ASMCs to
cause b2 AR desensitization, however both are possibilities, as it has
been shown that nucleotide fragments as small as 5 nucleotides long
can activate TLR 7/8 [32].
This in vitro model attempted to simulate the events of an in vivo
RV infection of the lung, which occurs principally in the airway
epithelium and may result in ASMC b2 AR desensitization.
However there are limitations to the current model that need to be
acknowledged. Primarily, the in vitro model involved only 2 cell
types, whilst physiologically there could be more cell types
involved during infection. For example inflammatory cells and
or perhaps other structural cells such as fibroblasts could play a
role. For this reason it is possible that other cells may be as
influential in causing b2 AR desensitization on ASMCs as
epithelial cells. Furthermore, when other cells are considered,
the system can become much more complex, and protein
mediators such as IL-1b which can also cause b2 AR desensiti-
zation [12,44] may also be involved. In addition, as it was shown
that each size fraction caused b2 AR desensitization, it does not
necessarily mean that it is only one small mediator that was
responsible. It is possible that there is a combination of multiple
sized mediators trapped in each fraction which could activate
GPCRs and cause b2 AR desensitization.
Although it was deduced in the current model that b2 AR
desensitization was due to RV RNA activating TLRs, in our
investigation RNA was extracted using a trizol methodology and
for this reason small RNA mediators such as RV-induced HBEC
derived micro (mi) RNA which may be able to activate TLRs [32]
and/or have their own undefined effect on b2 AR modulation
could also be responsible and requires further investigation. It is
theoretically possible to degrade the RNA in RV-induced
conditioned medium using exogenous ribonucleases and assess
for b2 AR desensitization. The limitation to this is that RNA that
has been degraded to as small as 5 nucleotides long may still be or
become immuno-stimulatory [32]. In a multicellular environment,
production of leukotrienes is also highly likely and can also cause
b2 AR desensitization, as it has been shown previously with LTD4
[15]. In addition, cytoplasmic helicase proteins such as retinoic-
acid-inducible protein I (RIG-I) and melanoma-differentiation-
associated gene 5 (MDA5) have been implicated in viral dsRNA
recognition [45]. During RV infection of epithelial cells TLR
activation is responsible for co-ordinating the up regulation of
RIG-I and MDA-5 which further induces antiviral responses [46].
Therefore, there is a possibility that activation of TLRs but also
RIG-I and MDA-5 by RV RNA could potentially contribute in a
co-ordinated manner to induce b2 AR desensitization and should
be investigated in future studies.
The second limitation of the in vitro model is the use of primary
human ASMCs and BEC which were obtained from multiple
disease tissue origins. The use of primary human cells is a better
representation of human cellular behaviour than some trans-
formed cell lines because they reflect more accurately the true
nature of biological heterogeneity of cellular responses, however
since the current model utilized two cell types which were not
diseased matched, and in some cases, HBEC derived conditioned
medium was pooled from multiple diseases, it might be possible
that asthma specific effects were missed.
Results from the present study identify the potential mediator
responsible for RV-induced b2 AR desensitization as viral RNA.
During RV replication, viral RNA increases and activates TLRs
and as a result induces COX-2 mediated prostaglandin production
which causes b2 AR dysfunction. Interestingly, the findings in this
study also raise the possibility that b2 AR desensitization may not
be entirely unique to RV infection but could also be caused by
other respiratory viruses that actively infect and replicate. By
extrapolating the current findings to the clinical situation, the
potential use of COX-2 inhibitors to restore b2 agonist efficacy in
asthmatic patients during viral infection is possible and could be
investigated clinically.
Supporting Information
Figure S1 Trypsin digestion of conditioned medium
removes IL-6 and IL-8. Conditioned medium pooled from
HBEC (n = 3) that were uninfected (Control) or treated with: UV
inactivated RV (UVi-RV) or replication competent RV (RV) at an
MOI = 2 for 24 hours was digested in the presence of 500 mg/mL
of trypsin for 24 hours at 37uC and the reaction was stopped with
0.1% BSA. IL-6 and IL-8 were measured using ELISA with n = 1
experimental repeat.
(TIF)
Figure S2 Trypsin digestion of conditioned medium still
causes ASMC b2 adrenoceptor desensitization.Conditioned
medium pooled from HBEC (n = 3) that were uninfected (Control)
or exposed to: UV inactivated RV (UVi-RV) or replication
competent RV (RV) at an MOI = 2 for 24 hours was digested in
the presence of 500 mg/mL of trypsin for 24 hours at 37uC and the
reaction was stopped with 0.1% BSA. ASMCs (n = 6) were treated
with trypsin digested conditioned medium for 3 days. Isoprenaline
induced cAMP was measured using a cAMP functional assay. Data
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represent mean6 SEM. Statistical differences were detected using a
1-way ANOVA with Bonferroni post test comparisons to control
conditioned medium *p,0.05.
(TIF)
Figure S3 Individual prostaglandin antagonists do not
prevent b2 adrenoceptor desensitization. ASMCs (n = 6)
were pretreated for 1 hr with vehicle (0.1% DMSO), CAY10441
(1026 M) (A), AH6809 (1025 M) (B), AL8810 (1025 M) (C),
BWA868C (1025 M) (D) or L-161,982 (1026 M) (E) and
maintained for a further 3 days in the presence of conditioned
medium from HBEC (n = 2) that were uninfected (Control) or
infected with replication competent RV (RV) at an MOI = 2 for 24
hours. Isoprenaline induced cAMP was measured using a cAMP
functional assay. Data represent mean 6 SEM. Statistical
differences were detected using 1-way ANOVA with Bonferroni
post test comparisons to the control conditioned medium
pretreatment in each group *p,0.05.
(TIF)
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